Regeneron says Covid-19 drug could be less effective against Omicron variant
Reuters
30 November, 2021, 05:20 pm
Last modified: 30 November, 2021, 05:22 pm
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid
Regeneron Pharmaceuticals Inc said on Tuesday prior analyses suggested its Covid-19 antibody drug could have reduced activity against the Omicron coronavirus variant.
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.